Indranil Dey, President and CEO of Bluejay Diagnostics, acquired 12,500 shares of common stock on March 14, 2026.
The shares were purchased at $2.00 each in a private placement, totaling $25,000. The stock currently trades near $1.72, close to its 52-week low of $1.65.
After the purchase, Dey directly holds 12,522 shares and indirectly holds 127 shares through an entity he co-owns.
The company's shares have declined about 77% over the past year, reflecting a challenging period for Bluejay Diagnostics.
